Awards Nomination 20+ Million Readerbase
PMC/PubMed Indexed Articles

Statistical considerations in biosimilar assessment using biosimilarity index

In-vitro Release of Rapamycin from a Thermosensitive Polymer for the Inhibition of Vascular Smooth Muscle Cell Proliferation

View More »

Google Scholar citation report
Citations : 4363

Journal of Bioequivalence & Bioavailability received 4363 citations as per Google Scholar report

Flyer image
Journal of Bioequivalence & Bioavailability peer review process verified at publons
Flyer image
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
View More
Useful Links
Share This Page
Journal Flyer
Flyer image
Open Access Journals
View More

Jeff Paul

Jeff Paul

Pfizer Inc, formerly Wyeth Research, Collegeville, Pennsylvania, USA

Biography
Dr. Paul is a clinical pharmacology consultant to the pharmaceutical industry, focusing his practice on early clinical development of drugs for CNS and pain. Dr. Paul has spent nearly 30 years in pharmaceutical R&D, including Discovery, and Phase 1 through 4 clinical development phases. He has global clinical and regulatory experience, especially in Europe and Japan. He has worked at Berlex, Pfizer (formally Wyeth), and Astellas at the Executive Director/Assistant VP level. 
Research Interest
Evaluation of the Potential of Cytochrome P450 3A4-Mediated Drug-Drug Interactions with Desvenlafaxine Use, Bioequiv Availability